Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) Director Timothy A. Springer bought 300,000 shares of Tectonic Therapeutic stock in a transaction dated Tuesday, October 22nd. The stock was acquired at an average price of $33.59 per share, with a total value of $10,077,000.00. Following the acquisition, the director now directly owns 4,096,764 shares of the company’s stock, valued at approximately $137,610,302.76. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Tectonic Therapeutic Trading Up 6.4 %
Shares of NASDAQ:TECX opened at $38.74 on Friday. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of 56.14 and a beta of 2.63. Tectonic Therapeutic has a 1 year low of $12.12 and a 1 year high of $39.40. The stock’s fifty day moving average price is $25.20.
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($3.81) earnings per share for the quarter, missing the consensus estimate of ($1.96) by ($1.85). On average, sell-side analysts anticipate that Tectonic Therapeutic will post -4.91 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Tectonic Therapeutic
Wall Street Analyst Weigh In
Several research analysts recently weighed in on TECX shares. Leerink Partners assumed coverage on Tectonic Therapeutic in a research report on Wednesday, July 24th. They set an “outperform” rating and a $49.00 price target on the stock. Leerink Partnrs upgraded Tectonic Therapeutic to a “strong-buy” rating in a report on Wednesday, July 24th. Finally, Wells Fargo & Company started coverage on shares of Tectonic Therapeutic in a research report on Thursday, August 22nd. They issued an “overweight” rating and a $55.00 price target for the company. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $60.00.
Read Our Latest Research Report on TECX
About Tectonic Therapeutic
Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.
See Also
- Five stocks we like better than Tectonic Therapeutic
- How Can Investors Benefit From After-Hours Trading
- Texas Roadhouse Stock Steering for New Highs This Year
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What does consumer price index measure?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.